Statement on the use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) in COVID-19 patients
Recent work suggested that patients on ACEi or ARBs upregulate ACE2 receptors, the binding site for SARS-CoV-2, within tissues including the lung and heart, prompting concern that this might place patients at risk of worse outcomes with COVID-19. For the moment, this remains purely theoretical, with no evidence of a linkage to poor clinical outcomes. In addition, discontinuing or switching ACEi or ARBs to alternative agents may be deleterious to patient care. Pending further evidence we therefore do not recommend switching patients off ACEi or ARBs unless there are other medical reasons to do so.
Answers extracted from: Clinical management of suspected or confirmed COVID-19 disease (Version 3, 27th March 2020)